Headache News

Vistagen announced that the U.S. Patent and Trademark Office granted a patent for the company’s investigational pherine PH80 nasal spray for the treatment of migraine.

A California-based biopharmaceutical company has announced the completion of its acquisition of Pherin Pharmaceuticals Inc., a drug development firm that specializes in neuropsychiatric and neuroendocrine issues.

An early return to school and other life activities following a concussion were associated with a lower symptom burden and faster recovery among children and adolescents, researchers reported in JAMA Network Open.

The most common neurological manifestations of COVID-19 for individuals living in Saudi Arabia were headache, changes in smell and taste, muscle pain, loss of consciousness and seizures, which were similar to global reports.

Despite the number of new medications produced to treat a range of neurologic diseases, limited utilization is driven by relatively high cost and similar efficacy to less expensive drugs, according to a study published in Neurology.

U.S. adults who reported a history of migraine or severe headache were 25% more likely to develop hypertension compared with those with no migraine history, with a higher risk for women vs. men, researchers reported.

Migraine has a bidirectional relationship with mental disorders such as anxiety and depression, and one may increase the risk of the other, researchers reported in Cureus.

Vistagen announced it has agreed to acquire Pherin Pharmaceuticals Inc., to bolster its efforts on discovery and development of therapeutics to treat a range of psychiatric and neuropsychiatric conditions.

Although cluster headaches may be more common in men, they may be more severe for women, researchers reported in Neurology.

Click Therapeutics announced it has received breakthrough device designation from the FDA for its digital therapeutic, CT-132, as an adjunctive preventive treatment for episodic migraines in those aged 18 years and older.